GRI Bio Secures New U.S. Patent Covering Novel Compound Structures for Immune Modulation

Reuters01-26
GRI Bio Secures New U.S. Patent Covering Novel Compound Structures for Immune Modulation

GRI Bio Inc. announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,528,775, granting composition-of-matter claims for a new class of proprietary compounds featuring pyrrolidine, piperidine, or azepane ring systems. The patent provides additional intellectual property protection for the company's platform of immunomodulators aimed at inflammatory, fibrotic, and autoimmune diseases. According to GRI Bio, this newly issued patent strengthens the company's IP estate by securing independent protection for a unique subset of its chemistry platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9642033) on January 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment